Neslihan Akanıl Fener
Journal of Current Hematology & Oncology Research - 2026;4(1):18-24
Aims: To investigate the frequency of SMARCA2 and SMARCA4 loss in epithelioid pleural mesothelioma and to evaluate their clinicopathologic correlates, with particular attention to the inflammatory tumor microenvironment. Methods: This retrospective study included 64 patients who underwent surgery for epithelioid pleural mesothelioma between January 2007 and October 2019. Results: Loss of SMARCA2 and SMARCA4 expression was detected in 4 patients each (6% for both markers). SMARCA2 loss was significantly associated with severe inflammation (p=0.02). Conclusion: SMARCA2 and SMARCA4 loss are uncommon events in epithelioid pleural mesothelioma. However, SMARCA2 deficiency was associated with a more pronounced lymphocytic/inflammatory infiltrate.
